BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38543812)

  • 21. Dynamics of Different Classes and Subclasses of Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants after Coronavirus Disease 2019 and CoronaVac Vaccination in Thailand.
    Poolchanuan P; Matsee W; Sengyee S; Siripoon T; Dulsuk A; Phunpang R; Pisutsan P; Piyaphanee W; Luvira V; Chantratita N
    mSphere; 2023 Feb; 8(1):e0046522. PubMed ID: 36688637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination.
    Madsen JR; Holm BE; Pérez-Alós L; Bayarri-Olmos R; Rosbjerg A; Fogh K; Pries-Heje MM; Møller DL; Hansen CB; Heftdal LD; Hasselbalch RB; Hamm SR; Frikke-Schmidt R; Hilsted L; Nielsen SD; Iversen KK; Bundgaard H; Garred P
    Microbiol Spectr; 2023 Mar; 11(2):e0494722. PubMed ID: 36877077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021.
    Budziar W; Gembara K; Harhala M; Szymczak A; Jędruchniewicz N; Baniecki K; Pikies A; Nahorecki A; Hoffmann A; Kardaś A; Szewczyk-Dąbrowska A; Klimek T; Kaźmierczak Z; Witkiewicz W; Barczyk K; Dąbrowska K
    PLoS One; 2022; 17(2):e0253638. PubMed ID: 35113873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term evolution of humoral immune response after SARS-CoV-2 infection.
    Teyssou E; Zafilaza K; Sayon S; Marot S; Dropy M; Soulie C; Abdi B; Tubach F; Hausfater P; Marcelin AG; Boutolleau D;
    Clin Microbiol Infect; 2022 Jul; 28(7):1027.e1-1027.e4. PubMed ID: 35307573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
    Stellini R; Gianello R; Gomarasca W
    Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
    Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
    Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
    Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
    Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
    Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P
    Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early humoral and cellular responses after bivalent SARS-CoV-2 mRNA-1273.214 vaccination in long-term care and retirement home residents in Ontario, Canada: An observational cohort study.
    Breznik JA; Rahim A; Bhakta H; Clare R; Zhang A; Ang J; Stacey HD; Liu LM; Kennedy A; Bilaver L; Hagerman M; Kajaks T; Bramson JL; Nazy I; Miller MS; Costa AP; Bowdish DME;
    J Med Virol; 2023 Oct; 95(10):e29170. PubMed ID: 37822054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eleven-month longitudinal study of antibodies in SARS-CoV-2 exposed and naïve primary health care workers upon COVID-19 vaccination.
    Dobaño C; Ramírez-Morros A; Alonso S; Ruiz-Olalla G; Rubio R; Vidal M; Prados de la Torre E; Jairoce C; Mitchell RA; Barrios D; Jiménez A; Rodrigo Melero N; Carolis C; Izquierdo L; Zanoncello J; Aguilar R; Vidal-Alaball J; Moncunill G; Ruiz-Comellas A
    Immunology; 2022 Dec; 167(4):528-543. PubMed ID: 36065677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine.
    Azzi L; Dalla Gasperina D; Veronesi G; Shallak M; Maurino V; Baj A; Gianfagna F; Cavallo P; Dentali F; Tettamanti L; Maggi F; Maffioli LS; Tagliabue A; Accolla RS; Forlani G
    EBioMedicine; 2023 Feb; 88():104435. PubMed ID: 36628844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
    Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
    Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ultrasensitive detection of salivary SARS-CoV-2 IgG antibodies in individuals with natural and COVID-19 vaccine-induced immunity.
    Thomas SN; Karger AB; Altawallbeh G; Nelson KM; Jacobs DR; Gorlin J; Barcelo H; Thyagarajan B
    Sci Rep; 2022 May; 12(1):8890. PubMed ID: 35614113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5-11 years old children with prior COVID-19.
    Di Chiara C; Cantarutti A; Raffaella Petrara M; Bonfante F; Benetti E; Boracchini R; Bosa L; Carmona F; Cosma C; Cotugno N; Le Prevost M; Martini G; Meneghel A; Pagliari M; Palma P; Ruffoni E; Zin A; De Rossi A; Giaquinto C; Donà D; Padoan A
    Vaccine; 2024 Jan; 42(2):263-270. PubMed ID: 38071105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2-specific mucosal immune response in vaccinated versus infected children.
    Conti MG; Piano Mortari E; Nenna R; Pierangeli A; Sorrentino L; Frasca F; Petrarca L; Mancino E; Di Mattia G; Matera L; Fracella M; Albano C; Scagnolari C; Capponi M; Cinicola B; Carsetti R; Midulla F
    Front Cell Infect Microbiol; 2024; 14():1231697. PubMed ID: 38601739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Saliva is suitable for SARS-CoV-2 antibodies detection after vaccination: A rapid systematic review.
    Guerra ENS; de Castro VT; Amorim Dos Santos J; Acevedo AC; Chardin H
    Front Immunol; 2022; 13():1006040. PubMed ID: 36203571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined monitoring of IgG and IgA anti-Spike and anti-Receptor binding domain long term responses following BNT162b2 mRNA vaccination in Greek healthcare workers.
    Sarrigeorgiou I; Moschandreou D; Dimitriadis A; Tsinti G; Sotiropoulou E; Ntoukaki E; Eliadis P; Backovic M; Labropoulou S; Escriou N; Pouliakis A; Giannopoulou G; Gaitanarou E; Lazaridis K; Mentis A; Mamalaki A; Grouzi E; Lymberi P
    PLoS One; 2022; 17(11):e0277827. PubMed ID: 36409702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 months.
    Younes S; Nicolai E; Al-Sadeq DW; Younes N; Al-Dewik N; Abou-Saleh H; Abo-Halawa BY; Eid AH; Pieri M; Liu N; Daas HI; Yassine HM; Nizamuddin PB; Abu-Raddad LJ; Nasrallah GK
    J Infect Public Health; 2023 Nov; 16(11):1729-1735. PubMed ID: 37734128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methodological approaches to optimize multiplex oral fluid SARS-CoV-2 IgG assay performance and correlation with serologic and neutralizing antibody responses.
    Pisanic N; Antar AAR; Kruczynski KL; Gregory Rivera M; Dhakal S; Spicer K; Randad PR; Pekosz A; Klein SL; Betenbaugh MJ; Detrick B; Clarke W; Thomas DL; Manabe YC; Heaney CD
    J Immunol Methods; 2023 Mar; 514():113440. PubMed ID: 36773929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.